TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heart scan study tests if new drug reduces dangerous protein buildup
Disease control OngoingThis study uses heart MRI scans to measure changes in amyloid protein buildup in patients with ATTR-CM, a serious heart condition. It involves up to 150 participants who are already enrolled in a larger trial testing an experimental drug called ION-682884 against a placebo. The g…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Heart drug gets 3-Year safety check in major patient study
Disease control ENROLLING_BY_INVITATIONThis study aims to check the long-term safety of a medication called eplontersen for people with a serious heart condition called ATTR-CM. About 1,400 patients who completed a previous study will receive the drug by injection every 4 weeks for up to 3 years. Researchers will moni…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Scans reveal if new drug clears deadly heart protein
Disease control OngoingThis study uses special heart scans to see if an investigational drug, eplontersen, can reduce the buildup of a harmful protein in the heart. It involves up to 150 people who already have a heart condition called ATTR amyloidosis and are part of a larger drug trial. The main goal…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC